10x Genomics (TXG) Competitors $15.08 -0.01 (-0.07%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends TXG vs. NVMI, VNT, ST, CAMT, MIR, TRNS, CTKB, LAB, EYPT, and AEHRShould you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Nova (NVMI), Vontier (VNT), Sensata Technologies (ST), Camtek (CAMT), Mirion Technologies (MIR), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), and Aehr Test Systems (AEHR). These companies are all part of the "measuring and control equipment" industry. 10x Genomics vs. Nova Vontier Sensata Technologies Camtek Mirion Technologies Transcat Cytek Biosciences Standard BioTools EyePoint Pharmaceuticals Aehr Test Systems Nova (NASDAQ:NVMI) and 10x Genomics (NASDAQ:TXG) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation. Which has more risk and volatility, NVMI or TXG? Nova has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Which has better earnings and valuation, NVMI or TXG? Nova has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Nova, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNova$517.92M13.74$136.31M$5.3645.6910x Genomics$618.73M2.95-$255.10M-$1.53-9.86 Is NVMI or TXG more profitable? Nova has a net margin of 28.00% compared to 10x Genomics' net margin of -28.93%. Nova's return on equity of 21.35% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets Nova28.00% 21.35% 14.34% 10x Genomics -28.93%-25.07%-19.41% Does the MarketBeat Community believe in NVMI or TXG? Nova received 395 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 74.38% of users gave Nova an outperform vote while only 52.38% of users gave 10x Genomics an outperform vote. CompanyUnderperformOutperformNovaOutperform Votes45074.38% Underperform Votes15525.62% 10x GenomicsOutperform Votes5552.38% Underperform Votes5047.62% Does the media favor NVMI or TXG? In the previous week, Nova had 2 more articles in the media than 10x Genomics. MarketBeat recorded 14 mentions for Nova and 12 mentions for 10x Genomics. Nova's average media sentiment score of 0.77 beat 10x Genomics' score of 0.43 indicating that Nova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nova 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of NVMI or TXG? 83.0% of Nova shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 1.0% of Nova shares are held by company insiders. Comparatively, 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend NVMI or TXG? Nova currently has a consensus price target of $238.33, suggesting a potential downside of 2.69%. 10x Genomics has a consensus price target of $23.86, suggesting a potential upside of 58.20%. Given 10x Genomics' higher probable upside, analysts plainly believe 10x Genomics is more favorable than Nova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nova 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.8610x Genomics 1 Sell rating(s) 7 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53 SummaryNova beats 10x Genomics on 12 of the 19 factors compared between the two stocks. Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXG vs. The Competition Export to ExcelMetric10x GenomicsAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.83B$5.92B$5.21B$9.14BDividend YieldN/A0.44%5.13%4.02%P/E Ratio-9.8629.9489.1817.36Price / Sales2.954.111,240.0477.11Price / CashN/A44.7543.7535.97Price / Book2.422.395.314.79Net Income-$255.10M$2.94M$122.54M$225.00M7 Day Performance-4.01%-1.43%0.59%2.62%1 Month Performance7.41%1.62%2.55%3.81%1 Year Performance-63.92%-20.91%25.29%20.10% 10x Genomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXG10x Genomics4.6252 of 5 stars$15.08-0.1%$23.86+58.2%-63.9%$1.83B$618.73M-9.861,240Analyst ForecastGap UpNVMINova1.8447 of 5 stars$215.63-1.0%$238.33+10.5%+69.6%$6.26B$611.85M40.233,606VNTVontier4.028 of 5 stars$35.85-0.3%$44.88+25.2%+6.2%$5.38B$2.99B13.748,000STSensata Technologies4.7198 of 5 stars$27.42+0.6%$41.00+49.5%-17.5%$4.10B$4.02B-50.7820,800Analyst ForecastNews CoveragePositive NewsCAMTCamtek3.6912 of 5 stars$86.61-3.3%$110.78+27.9%+31.6%$3.93B$400.63M39.91400Analyst ForecastShort Interest ↑Gap UpMIRMirion Technologies3.0017 of 5 stars$15.83-0.4%$19.25+21.6%+74.0%$3.68B$836.90M-46.563,000News CoverageGap UpTRNSTranscat2.9676 of 5 stars$102.86+0.3%$130.25+26.6%+1.0%$946.21M$270.61M51.95920News CoveragePositive NewsCTKBCytek Biosciences2.6008 of 5 stars$7.11+4.3%$9.25+30.1%-34.0%$915.85M$201.21M-88.86500Positive NewsLABStandard BioTools2.7616 of 5 stars$2.09+28.2%$2.88+37.6%-21.3%$778.02M$155.90M-2.94620High Trading VolumeEYPTEyePoint Pharmaceuticals1.7636 of 5 stars$7.74-7.2%$26.63+244.0%-66.5%$528.26M$45.71M-3.87120Short Interest ↑AEHRAehr Test Systems2.1872 of 5 stars$15.75-3.9%$25.00+58.7%-24.9%$466.69M$58.71M16.0790Earnings ReportGap Up Related Companies and Tools Related Companies Nova Alternatives Vontier Alternatives Sensata Technologies Alternatives Camtek Alternatives Mirion Technologies Alternatives Transcat Alternatives Cytek Biosciences Alternatives Standard BioTools Alternatives EyePoint Pharmaceuticals Alternatives Aehr Test Systems Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TXG) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TXG Stock Alerts